Dennis Cho Sells 689 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 689 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $25,940.85. Following the sale, the insider now directly owns 110,849 shares in the company, valued at $4,173,464.85. This represents a 0.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Dennis Cho also recently made the following trade(s):

• On Wednesday, April 2nd, Dennis Cho sold 124 shares of Twist Bioscience stock. The shares were sold at an average price of $38.73, for a total value of $4,802.52.
• On Thursday, March 20th, Dennis Cho sold 230 shares of Twist Bioscience stock. The shares were sold at an average price of $41.68, for a total value of $9,586.40.
• On Friday, March 14th, Dennis Cho sold 92 shares of Twist Bioscience stock. The shares were sold at an average price of $40.05, for a total transaction of $3,684.60.
• On Thursday, March 6th, Dennis Cho sold 277 shares of Twist Bioscience stock. The stock was sold at an average price of $40.91, for a total transaction of $11,332.07.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $32.67 on Friday. The stock has a market capitalization of $1.96 billion, a PE ratio of -9.66 and a beta of 2.54. The business’s 50 day simple moving average is $38.81 and its 200 day simple moving average is $43.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a one year low of $31.56 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc increased its stake in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after acquiring an additional 580 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. GAMMA Investing LLC boosted its position in shares of Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $34,000. Finally, Banque Transatlantique SA acquired a new stake in Twist Bioscience in the fourth quarter valued at approximately $43,000.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Barclays dropped their price objective on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, April 10th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. The Goldman Sachs Group cut their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday. Guggenheim reiterated a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday. Finally, Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.